Jazz Pharmaceuticals PLC (JAZZ) and Its Competitors Critical Review
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is one of 93 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Jazz Pharmaceuticals PLC to related companies based on the strength of its earnings, dividends, institutional ownership, valuation, profitability, risk and analyst recommendations.
This is a summary of recent ratings for Jazz Pharmaceuticals PLC and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Jazz Pharmaceuticals PLC||0||3||16||0||2.84|
|Jazz Pharmaceuticals PLC Competitors||163||543||1199||16||2.56|
Jazz Pharmaceuticals PLC presently has a consensus price target of $182.84, indicating a potential upside of 21.43%. As a group, “Biotechnology” companies have a potential upside of 147.56%. Given Jazz Pharmaceuticals PLC’s rivals higher probable upside, analysts plainly believe Jazz Pharmaceuticals PLC has less favorable growth aspects than its rivals.
Valuation and Earnings
This table compares Jazz Pharmaceuticals PLC and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Jazz Pharmaceuticals PLC||$1.54 billion||$758.97 million||23.34|
|Jazz Pharmaceuticals PLC Competitors||$223.74 million||$57.84 million||-0.65|
Jazz Pharmaceuticals PLC has higher revenue and earnings than its rivals. Jazz Pharmaceuticals PLC is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Jazz Pharmaceuticals PLC has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals PLC’s rivals have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.
Insider & Institutional Ownership
88.2% of Jazz Pharmaceuticals PLC shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 4.3% of Jazz Pharmaceuticals PLC shares are held by insiders. Comparatively, 20.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Jazz Pharmaceuticals PLC and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Jazz Pharmaceuticals PLC||25.69%||22.75%||9.14%|
|Jazz Pharmaceuticals PLC Competitors||-917.30%||-187.05%||-24.43%|
Jazz Pharmaceuticals PLC beats its rivals on 9 of the 13 factors compared.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.